HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5

Benzinga Newsdesk www.benzinga.com Positive 89.3%

Neg 0% Neu 0% Pos 89.3%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.